Processa Pharmaceuticals, Inc. (PCSA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 2.87 |
| Open | 2.8 |
| Day High | 2.87 |
| Day Low | 2.52 |
| 52-Week High | 14.25 |
| 52-Week Low | 1.67 |
| Volume | 129,515 |
| Average Volume | 64,079 |
| Market Cap | 7.2M |
| PE | -0.09 |
| EPS | -27.79 |
| Moving Average 50 Days | 2.33 |
| Moving Average 200 Days | 3.95 |
| Change | -0.27 |
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 12, 2026 2:15 PM GMT
VERO BEACH, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, today announced that George Ng, Chief Executive Officer
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
GlobeNewswire Inc.
Jan 05, 2026 2:15 PM GMT
Interim safety and efficacy data to be reported in Q1 VERO BEACH, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC) therapies, t
Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer
GlobeNewswire Inc.
Dec 17, 2025 1:00 PM GMT
Preliminary Phase 2 data demonstrate PCS6422+Capecitabine increased cancer-killing metabolite exposure while maintaining comparable safety to monotherapy capecitabine Company on track to conduct formal interim analysis in early 2026 VERO BEACH, Fla.,